Promising drug cocktail targets tough childhood cancers
NCT ID NCT07175415
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tests a combination of three drugs—capivasertib, venetoclax, and dexamethasone—in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first, to find the safest dose, and second, to see how well the treatment shrinks or eliminates cancer. It includes 42 participants whose tumors have specific genetic changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capivasertib, venetoclax, and dexamethasone
- What this could lead to
- If successful, this could offer a new treatment option for children with hard-to-treat leukemia or lymphoma that has come back or not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with only 42 participants, so results may not apply broadly. The drug combination may cause side effects or fail to control the disease long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Can a smart drug missile tame Hard-to-Treat leukemia?